ArticleFrontiers in cellular and infection microbiology2024
Preparation and evaluation of
Article in Frontiers in cellular and infection microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Rapid serological detection of smoothFrontiers in cellular and infection microbiology · 2026Article
- Development and evaluation of novel Brucella diagnostic antigen protein ST.BMC infectious diseases · 2025Article
- Application of Brucella type IV secretion proteins VirB1, VirB5, and VirB6 in the serological diagnosis of brucellosis.Scientific reports · 2025Article
- Unraveling brucellosis: advances in pathogenesis, diagnostic strategies, therapeutic innovations, and public health perspectives.Frontiers in medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Brucellosis, a significant zoonotic infectious disease, poses a global health threat. Accurate and efficient diagnosis is crucial for prevention, control, and treatment of brucellosis. VirB proteins, components of the Type IV secretion system (T4SS) in Methods: Tandem Mass Tag (TMT) proteomics technology was utilized to identify highly expressed VirB proteins from wild-type Results: Seven T4SS proteins (rVirB3, rVirB4, rVirB9, rBMEII0036, rVirB8, rVirB11, and rVirB10) were expressed used to construct the indirect ELISA method which showed high diagnostic accuracy. Sensitivity and specificity of the proteins exceeded 0.9100 and 0.9167, respectively, demonstrating good performance comparable to traditional LPS and Rose Bengal Ag antigens. Cross-reactivity was observed in a limited number of serum samples from febrile patients without brucellosis. Conclusions: The study highlights the potential of VirB proteins as novel diagnostic antigens for human brucellosis. Future research can further optimize the use of VirB proteins in diagnostic assays and explore their applications in vaccine development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.